跳至主要内容
临床试验/NCT04864899
NCT04864899已完成不适用

Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR)

The University of Hong Kong1 个研究点 分布在 1 个国家目标入组 112 人开始时间: 2021年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
112
试验地点
1
主要终点
The correlation of these myocardial characteristics to clinical symptoms at all time-points.

研究概览

简要总结

This is a prospective cohort study that aims to clinical significance of subclinical myocardial involvement in recovered COVID-19 patients using cardiovascular magnetic resonance.

详细描述

This study aims to:

  1. Determine the extent of myocardial involvement of COVID-19, as assessed by Cardiovascular Magnetic Resonance (CMR), 2 weeks after patient recovery, at 3-month post discharge and at 1-year post discharge.
  2. Correlate these myocardial characteristics to biventricular structure, function, blood biomarkers of inflammation, clinical symptoms, and functional capacity at all time points.
  3. Follow up recovered COVID-19 patients beyond the end of this study to assess for hard outcomes such as death, heart failure hospitalization, cardiac arrest and ventricular tachycardia/ fibrillation.

Recovered COVID-19 patients and age and gender matched controls subjects will be recruited.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Recovered COVID-19 patients
  • Definition of recovered COVID-19 patient:
  • COVID-19 diagnosis = established by a positive reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 [SARS-CoV2] and recovered from COVID-
  • Recovery = based on two criteria: (1) two negative nasopharyngeal swab RT-PCR results >24 hours apart and (2) absence of fever and improvement in respiratory symptoms.
  • Recovered non-COVID-19 patients with viral respiratory infections confirmed with viral polymerase chain reaction testing AND with a confirmed negative COVID-19 RT-PCR test.
  • Age and gender matched controls with no cardiac risk factors, not on cardiac medications, no history of myocardial infarction, heart failure or myocarditis, negative COVID-19 RT-PCR test and negative COVID-19 antibodies test.

排除标准

  • Previous myocardial infarction or myocarditis unrelated to COVID-19 infection
  • History of heart failure unrelated to COVID-19 infection
  • Presence of pacemakers or implantable cardiac defibrillators
  • Any contraindication for CMR testing
  • Renal impairment with eGFR <45ml/min/1.73m2
  • Limited life expectancy <1 year, for example due to pulmonary disease, cancer or significant hepatic failure
  • Refusal or inability to sign an informed consent.
  • Potential for non-compliance towards the requirements in the trial protocol (especially the medical treatment) or follow-up visits

结局指标

主要结局

The correlation of these myocardial characteristics to clinical symptoms at all time-points.

时间窗: 2 years

The correlation of these myocardial characteristics to biventricular structure at all time-points.

时间窗: 2 years

The correlation of these myocardial characteristics to biventricular function (CMR cine/strain) at all time-points.

时间窗: 2 years

The correlation of these myocardial characteristics to blood biomarkers of inflammation at all time-points.

时间窗: 2 years

The extent of myocardial involvement, as assessed by CMR tissue characterisation (T1/ T2/ ECV/ LGE), change from 2 weeks after patient recovery, at 3-months post discharge and at 1-year post discharge.

时间窗: 2 years

The correlation of these myocardial characteristics to functional capacity (6 minute walk test) at all time-points.

时间窗: 2 years

次要结局

  • Follow-up patients beyond the end of this study to assess for hard outcomes such as death.(2 years)
  • Follow-up patients beyond the end of this study to assess for hard outcomes such as heart failure hospitalisation.(2 years)
  • Follow-up patients beyond the end of this study to assess for hard outcomes such as cardiac arrest.(2 years)
  • Follow-up patients beyond the end of this study to assess for hard outcomes such as ventricular tachycardia/ fibrillation.(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Ng Ming-Yen

Clinical Assistant Professor

The University of Hong Kong

研究点 (1)

Loading locations...

相似试验